HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

PMDA

Regulatory intelligence
PMDAsafety guidance83% confidence

[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted

Source: PMDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as adenotonsillar hypertrophy treatment protocols.

Regulatory Analysis

PMDA regulatory document relevant to this signal.

Supporting Context

Therapeutic area
ENT · Surgical Intervention
Sub-indication
Ild

Related signal: Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children

Source

View source document

Related Signal

Open signal — Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.